SP
XTLB

SmartHarvest Portfolios’s XTL Biopharmaceuticals XTLB Stock Holding History

SmartHarvest Portfolios’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,351
Closed -$32.2K – 489
2026
Q1 		$32.2K Buy
+13,351
New +$42.3K 0.01% 375

Other funds holding XTLB

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SmartHarvest Portfolios's XTLB Position: Q2 2026 in Review

SmartHarvest Portfolios sold out of XTL Biopharmaceuticals (XTLB) in Q2 2026, closing a stake of 13,351 shares — an estimated $32.2K sold.

SmartHarvest Portfolios first reported a position in XTLB in Q1 2026 and held it in 1 quarter. The position peaked at $32.2K in Q1 2026. 3 funds tracked by Wall St. Rank hold XTLB as of Q2 2026.

  • SmartHarvest Portfolios reported no remaining XTL Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SmartHarvest Portfolios sold 13,351 XTL Biopharmaceuticals shares in Q2 2026, an estimated $32.2K.
  • SmartHarvest Portfolios first reported a position in XTL Biopharmaceuticals in Q1 2026 and held it in 1 quarter.
  • SmartHarvest Portfolios's XTL Biopharmaceuticals position peaked at $32.2K in Q1 2026.
  • 3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2026.

Based on SmartHarvest Portfolios's 13F filing for Q2 2026, filed 4 Aug 2026.